These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35398934)

  • 1. Clinicopathological prognostic parameters in patients with tubo-ovarian carcinoma effusions.
    Davidson B; Elstrand MB
    Cytopathology; 2022 Jul; 33(4):479-492. PubMed ID: 35398934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of L1CAM expression in metastatic tubo-ovarian high-grade serous carcinoma.
    Dos Santos MV; Holth A; Lindemann K; Staff AC; Davidson B
    Gynecol Oncol; 2023 Sep; 176():76-81. PubMed ID: 37478615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of palladin is associated with disease progression in metastatic high-grade serous carcinoma.
    Davidson B; Bock AJ; Holth A; Nymoen DA
    Cytopathology; 2020 Nov; 31(6):572-578. PubMed ID: 32741023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of EGFR, PD-L1, and the mismatch repair proteins before and following therapy in malignant serous effusions with metastatic high-grade serous tubo-ovarian carcinoma.
    Nikas IP; Park SY; Song MJ; Lee C; Ryu HS
    Diagn Cytopathol; 2024 Feb; 52(2):69-75. PubMed ID: 37937321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival.
    Brenne K; Nymoen DA; Hetland TE; Trope' CG; Davidson B
    Hum Pathol; 2012 Apr; 43(4):496-505. PubMed ID: 21855111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion.
    Davidson B; Smith Y; Nesland JM; Kærn J; Reich R; Tropè CG
    Hum Pathol; 2013 Nov; 44(11):2449-60. PubMed ID: 24011953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The phosphatase PTPN1/PTP1B is a candidate marker of better chemotherapy response in metastatic high-grade serous carcinoma.
    Davidson B; Bock AJ; Holth A; Nymoen DA
    Cytopathology; 2021 Mar; 32(2):161-168. PubMed ID: 33025675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Occludin is overexpressed in tubo-ovarian high-grade serous carcinoma compared to mesothelioma and is a marker of tumor progression and chemoresistance.
    Dos Santos MV; Holth A; Bischof K; Davidson B
    Clin Exp Metastasis; 2024 Feb; 41(1):69-76. PubMed ID: 38141113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Death domain-associated protein (DAXX) expression is associated with poor survival in metastatic high-grade serous carcinoma.
    Davidson B; McFadden E; Holth A; Brunetti M; Flørenes VA
    Virchows Arch; 2020 Dec; 477(6):857-864. PubMed ID: 32533344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble AXL is ubiquitously present in malignant serous effusions.
    Flem Karlsen K; McFadden E; Flørenes VA; Davidson B
    Gynecol Oncol; 2019 Feb; 152(2):408-415. PubMed ID: 30448261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anterior gradient protein 2 (AGR2) is an independent prognostic factor in ovarian high-grade serous carcinoma.
    Darb-Esfahani S; Fritzsche F; Kristiansen G; Weichert W; Sehouli J; Braicu I; Dietel M; Denkert C
    Virchows Arch; 2012 Aug; 461(2):109-16. PubMed ID: 22752467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma.
    Chen H; Molberg K; Strickland AL; Castrillon DH; Carrick K; Jiang Q; Niu S; Rivera-Colon G; Gwin K; Hinson S; Lea J; Miller DS; Zheng W; Lucas E
    Am J Surg Pathol; 2020 Aug; 44(8):1050-1060. PubMed ID: 32384321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TGFβ splicing and canonical pathway activation in high-grade serous carcinoma.
    Gutgold N; Davidson B; Catane LJ; Holth A; Hellesylt E; Tropé CG; Dørum A; Reich R
    Virchows Arch; 2017 Jun; 470(6):665-678. PubMed ID: 28432432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma.
    Eitan R; Levine DA; Abu-Rustum N; Sonoda Y; Huh JN; Franklin CC; Stevens TA; Barakat RR; Chi DS
    Cancer; 2005 Apr; 103(7):1397-401. PubMed ID: 15726548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and clinical role of long non-coding RNA in high-grade serous carcinoma.
    Filippov-Levy N; Cohen-Schussheim H; Tropé CG; Hetland Falkenthal TE; Smith Y; Davidson B; Reich R
    Gynecol Oncol; 2018 Mar; 148(3):559-566. PubMed ID: 29310950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival.
    Stavnes HT; Holth A; Don T; Kærn J; Vaksman O; Reich R; Trope' CG; Davidson B
    Gynecol Oncol; 2013 May; 129(2):358-63. PubMed ID: 23438671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival.
    Davidson B; Trope' CG; Wang TL; Shih IeM
    Gynecol Oncol; 2006 Dec; 103(3):814-9. PubMed ID: 16844205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Claudin-10 is a new candidate prognostic marker in metastatic high-grade serous carcinoma.
    Davidson B; Doutel D; Holth A; Nymoen DA
    Virchows Arch; 2023 Jun; 482(6):975-982. PubMed ID: 37067588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomic analysis of transitional cell carcinoma-like variant of tubo-ovarian high-grade serous carcinoma.
    Tessier-Cloutier B; Cochrane DR; Karnezis AN; Colborne S; Magrill J; Talhouk A; Zhang J; Leung S; Hughes CS; Piskorz A; Cheng AS; Greening K; du Bois A; Pfisterer J; Soslow RA; Kommoss S; Brenton JD; Morin GB; Gilks CB; Huntsman DG; Kommoss F
    Hum Pathol; 2020 Jul; 101():40-52. PubMed ID: 32360491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions.
    Davidson B; Reich R; Kopolovic J; Berner A; Nesland JM; Kristensen GB; Tropé CG; Bryne M; Risberg B; van de Putte G; Goldberg I
    Clin Exp Metastasis; 2002; 19(2):135-44. PubMed ID: 11964077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.